[사회]NovaVax vaccine’technology transfer’ first case…”Stable supply base”

Government-SK Bio signed a purchase contract for 20 million NovaVax vaccines
All produced in domestic factories… Signed a technology transfer contract
SK “Acquired the right to use NovaVax vaccine technology domestically”


[앵커]

It is also important that NovaVax’s COVID-19 vaccine produces 20 million people in Korea, but it is meaningful in that the technology transfer method was applied for the first time.

It is evaluated that it has established a stable supply base amid fierce competition for vaccines worldwide.

Reporter Park Hong-gu on the report.

[기자]

NovaVax, who had been discussing plans to introduce a COVID-19 vaccine with the Korean government for a month ago, signed a purchase contract.

SK Bioscience, a domestic manufacturer, decided to produce 20 million people in its domestic factory and signed a technology transfer contract.

SK explained that the meaning of technology transfer is to have the right to independently utilize NovaVax’s vaccine production technology in Korea, rather than simply consignment production.

This means that if more vaccines are needed, additional vaccines can be produced and sold at their own discretion without the approval of NovaVax headquarters.

[양동교 / 질병관리청 자원관리반장 : SK바이오사이언스에서 공급과 생산에 대한 권한을 함께 가지기 때문에 보다 안정적으로 우리나라에 백신공급이 가능해졌다고 평가할 수 있겠습니다.]

NovaVax vaccine is a synthetic antigen method applied to existing hepatitis B vaccines, and the immunity induction method is different from that of Pfizer and AstraZenekawa purchased by the government.

Currently, phase 3 clinical trials are in progress in the United States and other countries, and we plan to apply for an emergency license to the US Food and Drug Administration and FDA soon.

[정기석 / 한림대성심병원 호흡기내과 교수 : 예방효과가 90% 안팎을 넘나들 정도로 굉장히 좋고요. 스파이크 단백질이라는 단백질하고 가장 유사하게 생긴 것 자체를 집어넣어주는 겁니다.]

As the introduction of 20 million NovaVax supplies was confirmed amid the global competition to secure vaccines, the government’s vaccination plan was breathless.

NovaVax plans to determine specific vaccination targets after undergoing approval review by the Ministry of Food and Drug Safety when the results of phase 3 clinical trials are released, and through discussions with a vaccination committee.

This is YTN Park Hong-gu.

※’Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]

.Source